Eprosartan

DEA Class; Rx

Common Brand Names; Teveten

• ARBs

Angiotensin II antagonist; used once or twice daily for HTN; does not inhibit ACE or accumulate bradykinin; less likely to cause cough or angioedema than ACE inhibitors.

Indicated for the treatment of hypertension, either alone or in combination with other antihypertensive agents.

Hypersensitivity

Pregnancy (2nd/3rd trimesters): significant risk of fetal/neonatal morbidity and mortality

Bilateral renal artery stenosis

Do not coadminister with aliskiren in patients with diabetes

• Upper respiratory infection (8%)
• Cough (4%)
• Abdominal pain (2%)
• Fatigue (2%)
• Facial edema
• Dizziness
• Headache
• Neutropenia
• Back pain
• Myalgia

Angioedema, hypovolemia, hyperkalemia, surgery, and anesthesia

Discontinue STAT if pregnant: potential risk of congenital malformations (see Contraindications and Black Box Warnings)

Risk of hypotension, especially if hypovolemic/hyponatremic, or on concomitant diuretics or dialysis

Dual blockade of the renin angiotensin system with ARBs, ACE inhibitors, or aliskiren associated with increased risk for hypotension, hyperkalemia, and renal function changes (including acute renal failure) compared to monotherapy

Risk of anaphylactoid reactions and/or angioedema

Increased risk of renal dysfunction with CHF

Renal/hepatic impairment

Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters). During the second and third trimesters of pregnancy, these drugs have been associated with fetal injury that includes hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death

Lactation: excretion in milk unknown/not recommended